About the cover

PSMA-SPECT/CT and PCa metastatic lesions


mCRPC therapies: choices and questions


Using conventional imaging modalities, it is difficult to detect recurrent lesions in prostate cancer patients who have undergone biochemical relapse. We retrospectively reviewed fifty patients with histopathologically confirmed prostate cancer who underwent 99mTc labeled PSMA-SPECT/CT, MRI, and bone scan. PSMA-SPECT/CT indicated metastatic lesions in 39 patients and had a higher detection rate than bone scan or MRI. The diagnostic efficiency of PSMA-SPECT/CT imaging for bone and lymph node metastases was better than bone scan or MRI. PSMA SPECT/ CT provided a higher detection rate at different PSA levels. No correlation was found between Gleason score, PSA level, and the tracer tumor/background ratio of metastatic lesions. With the aid of PSMA SPECT/CT imaging, the therapeutic strategy was changed for 31 patients, and this may have enhanced their clinical outcome. In conclusion, PSMA SPECT/CT imaging could achieve a higher detection rate than conventional imaging modalities in prostate cancer patients who had undergone biochemical relapse. Please refer to pages 267–271 by Su et al. for details. (Artwork is displayed by Xiang Chen)

Feedback
Editorial board
Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal